Metastatic melanoma: which BRAF/MEK inhibitor combination is best?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Indirect comparison of dabrafenib (Tafinlar) plus trametinib (Mekinist) with vemurafenib (Zelboraf) plus cobimetinib (Cotellic) suggests the 2 combinations have similar efficacy in metastatic melanoma, but adverse events are lower with dabrafenib plus trametinib.
Why this matters
  • These findings can help providers in the decision-making process when they are evaluating available options of BRAF/MEK inhibitor combinations for this population.
Study design
  • As there are no head-to-head studies, an indirect comparison was performed between dabrafenib plus trametinib and vemurafenib plus cobimetinib; 2 randomized trials were identified (dabrafenib plus trametinib vs vemurafenib with 704 patients and vemurafenib plus cobimetinib vs vemurafenib plus placebo with 495 patients).
  • Funding: Novartis.
Key results
  • T...